100 related articles for article (PubMed ID: 15182620)
1. [Preventive and therapeutic effect of genetic vaccine based on recombinant alpha virus against mouse mastocytoma P815].
Ni B; Yang RG; Li YQ; Wu YZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):45-8. PubMed ID: 15182620
[TBL] [Abstract][Full Text] [Related]
2. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.
Ni B; Lin Z; Zhou L; Wang L; Jia Z; Zhou W; Diciommo DP; Zhao J; Bremner R; Wu Y
Cancer Detect Prev; 2004; 28(6):418-25. PubMed ID: 15582265
[TBL] [Abstract][Full Text] [Related]
3. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
5. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
7. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus].
Liu YZ; Zhou L; Wang Q; Ye SQ; Li HX; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):251-4. PubMed ID: 15640860
[TBL] [Abstract][Full Text] [Related]
8. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
9. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
11. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.
Vandermeulen G; Uyttenhove C; De Plaen E; Van den Eynde BJ; Préat V
Bioelectrochemistry; 2014 Dec; 100():112-8. PubMed ID: 24342164
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.
Colmenero P; Chen M; Castaños-Velez E; Liljeström P; Jondal M
Int J Cancer; 2002 Apr; 98(4):554-60. PubMed ID: 11920615
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.
Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T
Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
16. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
[TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
18. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
20. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.
Zhou X; Berglund P; Zhao H; Liljeström P; Jondal M
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):3009-13. PubMed ID: 7708765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]